KR102563829B1 - 거대고리 rip2 키나아제 억제제 - Google Patents

거대고리 rip2 키나아제 억제제 Download PDF

Info

Publication number
KR102563829B1
KR102563829B1 KR1020177010128A KR20177010128A KR102563829B1 KR 102563829 B1 KR102563829 B1 KR 102563829B1 KR 1020177010128 A KR1020177010128 A KR 1020177010128A KR 20177010128 A KR20177010128 A KR 20177010128A KR 102563829 B1 KR102563829 B1 KR 102563829B1
Authority
KR
South Korea
Prior art keywords
alkyl
halo
het
compound
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177010128A
Other languages
English (en)
Korean (ko)
Other versions
KR20170048596A (ko
Inventor
잔 호프락
페트라 블롬
파스칼 벤데리테르
Original Assignee
온코디자인 에스.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 온코디자인 에스.에이. filed Critical 온코디자인 에스.에이.
Publication of KR20170048596A publication Critical patent/KR20170048596A/ko
Application granted granted Critical
Publication of KR102563829B1 publication Critical patent/KR102563829B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020177010128A 2014-09-17 2015-09-17 거대고리 rip2 키나아제 억제제 Active KR102563829B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14185130 2014-09-17
EP14185130.3 2014-09-17
PCT/EP2015/071347 WO2016042087A1 (en) 2014-09-17 2015-09-17 Macrocyclic rip2 kinase inhibitors

Publications (2)

Publication Number Publication Date
KR20170048596A KR20170048596A (ko) 2017-05-08
KR102563829B1 true KR102563829B1 (ko) 2023-08-03

Family

ID=51687776

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177010128A Active KR102563829B1 (ko) 2014-09-17 2015-09-17 거대고리 rip2 키나아제 억제제

Country Status (26)

Country Link
US (1) US10676486B2 (enExample)
EP (1) EP3194407B1 (enExample)
JP (1) JP6736545B2 (enExample)
KR (1) KR102563829B1 (enExample)
CN (1) CN106687464B (enExample)
AU (1) AU2015316799B2 (enExample)
BR (1) BR112017004035B1 (enExample)
CA (1) CA2958782C (enExample)
DK (1) DK3194407T3 (enExample)
EA (1) EA032872B1 (enExample)
ES (1) ES2763344T3 (enExample)
HR (1) HRP20192334T1 (enExample)
HU (1) HUE048518T2 (enExample)
IL (1) IL250544B (enExample)
LT (1) LT3194407T (enExample)
MX (1) MX376087B (enExample)
MY (1) MY186523A (enExample)
PL (1) PL3194407T3 (enExample)
PT (1) PT3194407T (enExample)
SA (1) SA517381087B1 (enExample)
SG (1) SG11201701116XA (enExample)
SI (1) SI3194407T1 (enExample)
TW (1) TWI709563B (enExample)
UA (1) UA121315C2 (enExample)
WO (1) WO2016042087A1 (enExample)
ZA (1) ZA201701331B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102719387B1 (ko) * 2017-01-26 2024-10-21 한미약품 주식회사 이미다조피리다진 화합물
UY39061A (es) 2020-01-31 2022-01-31 Oncodesign Sa Inhibidores macrocíclicos de rip2-cinasa
CN117659043A (zh) * 2022-09-07 2024-03-08 苏州朗睿生物医药有限公司 一种大环咪唑并[1,2-b]哒嗪衍生物及其制备方法和用途
WO2024146541A1 (en) * 2023-01-03 2024-07-11 Guangdong Newopp Biopharmaceuticals Co., Ltd. Macrocyclic compounds as usp1 inhibitors
WO2025212514A2 (en) * 2024-04-02 2025-10-09 Interline Therapeutics, Inc. Methods of treating inflammatory diseases

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011146336A1 (en) 2010-05-20 2011-11-24 Array Biopharma Inc. Macrocyclic compounds as trk kinase inhibitors
WO2013001310A1 (en) 2011-06-30 2013-01-03 Centro Nacional De Investigaciones Oncológicas (Cnio) Macrocyclic compounds and their use as cdk8 inhibitors
WO2013045653A1 (en) 2011-09-30 2013-04-04 Oncodesign S.A. Macrocyclic flt3 kinase inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IS2334B (is) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
SG48049A1 (en) 1993-10-01 1998-04-17 Astra Ab Process i
US6043358A (en) 1995-11-01 2000-03-28 Merck & Co., Inc. Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
CN101600718B (zh) * 2006-11-06 2013-07-03 特雷罗药物股份有限公司 咪唑并[1,2-b]哒嗪和吡唑并[1,5-a]嘧啶衍生物及其作为蛋白激酶抑制剂的用途
AR077468A1 (es) * 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
TWI547494B (zh) 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
UA113186C2 (xx) 2011-09-30 2016-12-26 Макроциклічні інгібітори lrrk2 кінази

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011146336A1 (en) 2010-05-20 2011-11-24 Array Biopharma Inc. Macrocyclic compounds as trk kinase inhibitors
WO2013001310A1 (en) 2011-06-30 2013-01-03 Centro Nacional De Investigaciones Oncológicas (Cnio) Macrocyclic compounds and their use as cdk8 inhibitors
WO2013045653A1 (en) 2011-09-30 2013-04-04 Oncodesign S.A. Macrocyclic flt3 kinase inhibitors

Also Published As

Publication number Publication date
US20190127390A1 (en) 2019-05-02
SI3194407T1 (sl) 2020-03-31
PL3194407T3 (pl) 2020-04-30
BR112017004035A8 (pt) 2023-05-09
AU2015316799A1 (en) 2017-04-27
HUE048518T2 (hu) 2020-07-28
ES2763344T3 (es) 2020-05-28
MX376087B (es) 2025-03-07
BR112017004035B1 (pt) 2023-11-14
MX2017003469A (es) 2017-05-08
CN106687464B (zh) 2020-03-03
JP2017528481A (ja) 2017-09-28
IL250544B (en) 2020-06-30
NZ730758A (en) 2023-09-29
EP3194407A1 (en) 2017-07-26
WO2016042087A1 (en) 2016-03-24
ZA201701331B (en) 2020-07-29
EA201790609A1 (ru) 2017-07-31
CN106687464A (zh) 2017-05-17
IL250544A0 (en) 2017-03-30
KR20170048596A (ko) 2017-05-08
BR112017004035A2 (pt) 2017-12-05
TWI709563B (zh) 2020-11-11
HRP20192334T1 (hr) 2020-03-20
CA2958782A1 (en) 2016-03-24
MY186523A (en) 2021-07-24
DK3194407T3 (da) 2020-01-27
EA032872B1 (ru) 2019-07-31
TW201619168A (zh) 2016-06-01
US10676486B2 (en) 2020-06-09
LT3194407T (lt) 2020-01-27
CA2958782C (en) 2024-01-09
SA517381087B1 (ar) 2021-02-09
SG11201701116XA (en) 2017-03-30
JP6736545B2 (ja) 2020-08-05
PT3194407T (pt) 2020-01-20
EP3194407B1 (en) 2019-10-23
AU2015316799B2 (en) 2019-07-11
UA121315C2 (uk) 2020-05-12

Similar Documents

Publication Publication Date Title
JP6082397B2 (ja) マクロ環状ｌｒｒｋ２キナーゼ阻害剤
JP2023521321A (ja) 疾患の治療用のホスホイノシチド３－キナーゼ（ｐｉ３ｋ）のアロステリッククロメノン阻害剤
EP2945623A1 (en) Hedgehog pathway signaling inhibitors and therapeutic applications thereof
KR20150133765A (ko) 거대고리 rip2 키나제 억제제
KR102563829B1 (ko) 거대고리 rip2 키나아제 억제제
CN105209040A (zh) 大环的盐可诱导的激酶抑制剂
CA3066979A1 (en) Chemical compounds as h-pgds inhibitors
KR20190066631A (ko) 피리도[3,4-d]피리미딘 유도체 및 그 약학적으로 허용되는 염
TW202438054A (zh) 作為ＭＴＡ－協同ＰＲＭＴ５抑制劑的５－胺基－６，８－二氫－１Ｈ－呋喃并［３，４－ｄ］吡咯并［３，２－ｂ］吡啶－２－甲醯胺衍生物
JP2024539633A (ja) 置換１Ｈ－ピラゾロ［４，３－ｃ］キノリン、その調製方法、および使用
CN111163775A (zh) 作为cdk8/cdk19抑制剂的新型[1,6]萘啶化合物和衍生物
HK1232862B (zh) 大环rip2激酶抑制剂
HK1232862A1 (en) Macrocyclic rip2 kinase inhibitors
NZ730758B2 (en) Macrocyclic rip2 kinase inhibitors
EP2968325A1 (en) Macrocyclic rip2 kinase inhibitors
EP2968326A1 (en) Macrocyclic salt-inducible kinase inhibitors

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301